Skip to main content

Table 1 Baseline characteristics of study participants

From: Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine

CharacteristicAS+DP
N = 79
AS+AL
N = 71
QN + DP
N = 71
QN + AL
N = 79
Female (%)36 (45.6)36 (50.7)24 (33.8)37 (46.8)
Age in months*17 (11–26)16 (10–26)17 (13–26)18 (13–26)
Weight (kgs)*9.5 (8–11.5)9 (8.1–11)9.8 (8.8–11)9.2 (8.4–11)
Temperature (degrees Centigrade)*38.8 (37.7–39.5)39.1 (37.7–39.5)39.1 (37.3–39.5)38.6 (37.5–39.6)
Parasite density per uL, log10 copies*4.82 (4.29–5.10)4.79 (4.38–5.02)4.72 (4.19–5.00)4.73 (4.17–5.03)
Complications at admission, n (%)
 Hemoglobin (mg/dL)*9.1 (7.9–10.5)9.2 (8.4–10.6)9.3 (8.4–10.4)9.4 (8.0–10.3)
 Total white blood cell count (*103/uL)*9.6 (6.9–13.2)9.2 (7.5–12.3)9.4 (7.7–12.1)10.0 (7.0–14.3)
 Random blood sugar (mmol/L)*7.3 (6.3–8.3)6.8 (6.4–8.3)6.8 (5.7–8.3)7.4 (6.25–8.25)
 History of repeated convulsions n (%)6 (7.6%)3 (4.2%)8 (11.3%)1 (1.3%)
 History of inability to feed26 (33.0%)24 (34.0%)22 (31.0%)29 (36.7%)
 Prostration (extreme weakness)22 (27.9%)15 (21.13%)21 (29.58%)21 (26.58%)
 Hemoglobinuria002 (2.8%)0
 Jaundice2 (2.5%)03 (4.2%)3 (3.8%)
 Severe anemia001 (3%)2 (2.5%)
 Respiratory distress2 (2.5%)6 (8.5%)3 (4.2%)5 (6.3%)
 Impaired consciousness001 (1.4%)0
 Abnormal bleeding2 (2.5%)1 (1.4%)01 (1.3%)
 Hypoglycemia0001 (1.3%)